ResMed (NYSE:RMD) Shares Unloaded Rep. Kelly Morrison

Representative Kelly Morrison (D-Minnesota) recently sold shares of ResMed Inc. NYSE: RMD. In a filing disclosed on June 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in ResMed stock on June 4th. The trade occurred in the Representative's "TRUST 2" account.

Representative Kelly Morrison also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 6/4/2025.
• Sold $1,001 - $15,000 in shares of Houlihan Lokey NYSE: HLI on 6/4/2025.
• Sold $1,001 - $15,000 in shares of Zebra Technologies NASDAQ: ZBRA on 6/4/2025.
• Sold $1,001 - $15,000 in shares of NIKE NYSE: NKE on 6/4/2025.
• Sold $1,001 - $15,000 in shares of WEX NYSE: WEX on 6/4/2025.
• Sold $15,001 - $50,000 in shares of Zebra Technologies NASDAQ: ZBRA on 6/4/2025.
• Sold $1,001 - $15,000 in shares of ResMed NYSE: RMD on 4/28/2025.
• Purchased $15,001 - $50,000 in shares of Meta Platforms NASDAQ: META on 4/11/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 4/11/2025.
• Purchased $15,001 - $50,000 in shares of Broadcom NASDAQ: AVGO on 4/11/2025.

ResMed Trading Up 0.5%

Shares of ResMed stock opened at $257.64 on Friday. ResMed Inc. has a 52-week low of $196.43 and a 52-week high of $263.05. The company has a quick ratio of 2.49, a current ratio of 3.41 and a debt-to-equity ratio of 0.12. The company's 50-day simple moving average is $251.53 and its 200-day simple moving average is $237.58. The firm has a market cap of $37.78 billion, a price-to-earnings ratio of 28.92, a price-to-earnings-growth ratio of 1.61 and a beta of 0.77.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.36 by $0.01. ResMed had a net margin of 26.15% and a return on equity of 25.67%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the business posted $2.13 earnings per share. The business's revenue was up 7.9% compared to the same quarter last year. As a group, equities research analysts anticipate that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th were paid a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, May 8th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.82%. ResMed's dividend payout ratio (DPR) is 23.79%.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. UBS Group decreased their price objective on shares of ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada upgraded shares of ResMed from a "sector perform" rating to an "outperform" rating and lifted their target price for the stock from $255.00 to $294.00 in a research report on Tuesday, July 15th. JPMorgan Chase & Co. lifted their target price on shares of ResMed from $286.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, April 24th. Mizuho lifted their target price on shares of ResMed from $250.00 to $270.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, KeyCorp set a $274.00 target price on shares of ResMed in a research report on Thursday, April 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $263.00.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 8,009 shares of ResMed stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $256.72, for a total transaction of $2,056,070.48. Following the sale, the chief executive officer directly owned 455,503 shares of the company's stock, valued at approximately $116,936,730.16. The trade was a 1.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Peter C. Farrell sold 945 shares of ResMed stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $255.49, for a total value of $241,438.05. Following the sale, the director directly owned 68,273 shares in the company, valued at approximately $17,443,068.77. The trade was a 1.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 29,013 shares of company stock valued at $7,238,913 over the last 90 days. 0.71% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Consolidated Planning Corp raised its holdings in ResMed by 11.8% in the second quarter. Consolidated Planning Corp now owns 5,078 shares of the medical equipment provider's stock valued at $1,310,000 after buying an additional 534 shares during the period. Robeco Institutional Asset Management B.V. raised its holdings in ResMed by 7.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 83,451 shares of the medical equipment provider's stock valued at $21,530,000 after buying an additional 6,009 shares during the period. Pacific Point Advisors LLC raised its holdings in ResMed by 5.8% in the second quarter. Pacific Point Advisors LLC now owns 6,220 shares of the medical equipment provider's stock valued at $1,605,000 after buying an additional 341 shares during the period. Institute for Wealth Management LLC. purchased a new position in ResMed in the second quarter valued at approximately $260,000. Finally, Truist Financial Corp grew its position in ResMed by 1.7% in the second quarter. Truist Financial Corp now owns 10,660 shares of the medical equipment provider's stock valued at $2,750,000 after acquiring an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 54.98% of the company's stock.

About Representative Morrison

Kelly Morrison (Democratic Party) is a member of the U.S. House, representing Minnesota's 3rd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027. Morrison (Democratic Party) is running for re-election to the U.S. House to represent Minnesota's 3rd Congressional District. She declared candidacy for the 2026 election. Kelly Morrison was born in Minneapolis, Minnesota, and lives in Deephaven. Morrison earned a B.A. in history from Yale University and an M.D. from Case Western Reserve University. She completed her residency in obstetrics and gynecology at Northwestern University. Morrison's career experience includes working as a physician.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.